Keros reported a net loss of $30.7 million in the second quarter of 2025 as compared to a net loss of $45.3 million in the second quarter of 2024. The decrease of $14.6 million was largely due to ...
LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...
Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, ...
Jan 15 (Reuters) - Keros Therapeutics (KROS.O), opens new tab said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage ...
Keros Therapeutics has shaken up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on an early-stage Duchenne muscular dystrophy (DMD ...
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback